Bone Biologics Corporation
Symbole: BBLG
NASDAQ
1.8001
USDPrix du marché aujourd'hui
-0.1011
Ratio P/E
0.0004
Ratio PEG
1.58M
Cap MRK
- 0.00%
Rendement DIV
Bone Biologics Corporation (BBLG) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | -0.3 | -0.6 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.7 | 1 | 0 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.4 | 0 | 0.1 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | -0.8 | 0 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 0.5 | 2.5 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 0.8 | 2.5 | 0.1 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -80.9 | -72 | -70.5 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 83.8 | 77.9 | 77 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -3 | -7.5 | -6.7 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.3 | 0.2 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.1 | -0.2 | -0.3 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.8 | -0.4 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.1 | -1 | 0 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -2.2 | 0.5 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 5 | 4.4 | 6.9 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 1.1 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5 | 4.4 | 7.9 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -4.5 | 0.9 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 7.5 | 6.7 | 0 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -9.6 | -3.6 | -1.2 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -9.6 | -3.6 | -1.2 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 9.4 | -0.7 | 0 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | -9.4 | -3.7 | -1.1 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | -2.2 | 0 | ||||||||||||||||
income-statement-row.row.net-income | 0 | -8.9 | 0.7 | -1.6 |
Questions fréquemment posées
Quel est le total de Bone Biologics Corporation (BBLG) de l'actif total?
Bone Biologics Corporation (BBLG) Le total des actifs est 3737763.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est N/A.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.000.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est -17.887.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est 0.000.
Quel est le revenu total de l'entreprise?
Le revenu total est 0.000.
Qu'est-ce que Bone Biologics Corporation (BBLG) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est -8948731.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 0.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 9428303.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 0.000.